Cancer
-
Combo of cabozantinib plus atezolizumab active across kidney cancer subtypes
September 9, 2021 By Gregor Kreth Recent findings based on the phase 1b COSMIC-021 trial in Ā Journal of Clinical Oncology…
Read More » -
US FDA Approves Belzutifan for Tumors Associated With Certain Types of Von Hippel-Lindau Disease
By Gregor Kreth, Guest Writer August 16, 2021 FDA approves Merckās Welireg for the treatment of adult patients with von…
Read More » -
Medical Disclaimer
– The contents of the GUcancers Site, such as text, graphics, images, and other material contained on the GUcancers Site…
Read More » -
TERMS AND CONDITIONS OF USE
PLEASE READ THE FOLLOWING TERMS AND CONDITIONS OF USE (THE āTERMSā) CAREFULLY BEFORE USING THIS WEB SITE (THE āSITEā) AND…
Read More » -
Advertising Policy
GUcancers accepts advertising on the GUcancers Network from third parties (“Advertisers”), which may include third party banners, badges, contextual advertising…
Read More » -
Editorial policy
GUcancers.com and its affiliates (āGUCancersā or “Biomedz” or āweā), which operate www.GUcancers.com (āGUCancersā), are committed to providing GUCancers users with…
Read More » -
ASCO21 Meeting Summary – Kidney Cancer
Practice Changing Results in RCC come from ASCO 2021 Ochsner Precision Cancer Therapies Program and Ochsner Cancer Institute, Benson Cancer…
Read More » -
ASCO21 Sessions: RECOMMENDED ABSTRACTS in Renal Cancer
These recommended abstracts have been selected by Robert A. Figlin, MD, Editor-in- Chief of the Kidney Cancer Journal. The chosen abstracts provided…
Read More » -
MEDICAL INTELLIGENCE – Kidney Cancer
Newsworthy, late-breaking kidney cancer information from Web-based sources, professional societies, and government agencies FDA Approves Tivozanib as First Therapy for…
Read More » -
Roundtable Discussion – Cancer and COVID-19
Robert J. Motzer, MDĀ¹, Eric A. Jonasch, MD2,Bradley A. McGregor, MD3, Robert A. Figlin, MD, FACP4 1 Memorial Sloan Kettering…
Read More »
